C12N 2750/14122
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2750/14122 (New viral proteins or individual genes, new structural or functional aspects of) appears on 589 US grants and 1,404 published applications in this corpus.
Search patents in C12N- Granted patents
- 589
- Published applications
- 1,404
- Assignees
- 408
- Inventors
- 1,926
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 5 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 1 |
| 2002 | 7 | 18 |
| 2003 | 6 | 12 |
| 2004 | 3 | 18 |
| 2005 | 2 | 10 |
| 2006 | 11 | 11 |
| 2007 | 11 | 9 |
| 2008 | 3 | 13 |
| 2009 | 5 | 13 |
| 2010 | 5 | 14 |
| 2011 | 5 | 11 |
| 2012 | 6 | 14 |
| 2013 | 10 | 18 |
| 2014 | 14 | 19 |
| 2015 | 17 | 28 |
| 2016 | 13 | 26 |
| 2017 | 31 | 47 |
| 2018 | 21 | 48 |
| 2019 | 30 | 59 |
| 2020 | 38 | 81 |
| 2021 | 48 | 111 |
| 2022 | 36 | 132 |
| 2023 | 49 | 153 |
| 2024 | 69 | 170 |
| 2025 | 63 | 211 |
| 2026 | 60 | 157 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for delivery of agents across the blood-brain barrier29 Sep 2026US 12,747,269 B2The Brigham and Women S Hospital, Inc.
- Inactive telomerase, adenovirus associated virus and artificial mRNA having same and use thereof22 Sep 2026US 12,742,161 B2Nanjing Juvensis Therapuetics Co., Ltd.
- Adeno-associated viral vector variants15 Sep 2026US 12,734,252 B2The Children’s Hospital of Philadelphia
- Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof15 Sep 2026US 12,735,459 B2Genzyme Corporation
- Engineered adeno-associated (AAV) vectors for transgene expression15 Sep 2026US 12,735,721 B2President and Fellows of Harvard College
- Capsids and methods of targeting neurons8 Oct 2026US 2026/0306661 A1Capsigen Inc.
- Targeting aav capsids, methods of manufacturing and using same8 Oct 2026US 2026/0308615 A1REGENXBIO Inc.
- Compositions and methods for recombinant aav production8 Oct 2026US 2026/0308620 A1REGENXBIO Inc.
- Single plasmid system for aav production8 Oct 2026US 2026/0308623 A1Solid Biosciences Inc.
- Compositions and Methods for Increasing AAV Productivity8 Oct 2026US 2026/0308624 A1Oxford Biomedica (US) LLC
Most cited
By later US patents
- Adeno-associated virus as eukaryotic expression vector481US 4,797,368 AThe United States of America as represented by the Department of Health and Human Services · 1989
- Production of recombinant adeno-associated virus vectors369US 5,173,414 AApplied Immune Sciences, Inc. · 1992
- Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom352US 6,156,303 AUniversity of Washington · 2000
- Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor346US 7,906,111 B2The Trustees of the University of Pennsylvania · 2011
- Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor288US 7,282,199 B2The Trustees of the University of Pennsylvania · 2007